IN2014KN02769A - - Google Patents
Info
- Publication number
- IN2014KN02769A IN2014KN02769A IN2769KON2014A IN2014KN02769A IN 2014KN02769 A IN2014KN02769 A IN 2014KN02769A IN 2769KON2014 A IN2769KON2014 A IN 2769KON2014A IN 2014KN02769 A IN2014KN02769 A IN 2014KN02769A
- Authority
- IN
- India
- Prior art keywords
- diagnosis
- treatment
- methods
- relates
- hpv
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
- G01N2333/04—Varicella-zoster virus
- G01N2333/045—Cytomegalovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/186—Hepatitis C; Hepatitis NANB
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261656256P | 2012-06-06 | 2012-06-06 | |
| PCT/EP2013/061751 WO2013182661A1 (en) | 2012-06-06 | 2013-06-06 | Peptides derived from viral proteins for use as immunogens and dosage reactants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN02769A true IN2014KN02769A (OSRAM) | 2015-05-08 |
Family
ID=48577073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2769KON2014 IN2014KN02769A (OSRAM) | 2012-06-06 | 2013-06-06 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10501499B2 (OSRAM) |
| EP (1) | EP2859011B1 (OSRAM) |
| JP (1) | JP6310909B2 (OSRAM) |
| KR (1) | KR20150018870A (OSRAM) |
| CN (1) | CN104619718A (OSRAM) |
| AU (1) | AU2013273482A1 (OSRAM) |
| BR (1) | BR112014030466A2 (OSRAM) |
| CA (1) | CA2874923C (OSRAM) |
| EA (1) | EA201492262A1 (OSRAM) |
| HK (1) | HK1207871A1 (OSRAM) |
| IL (1) | IL235891A0 (OSRAM) |
| IN (1) | IN2014KN02769A (OSRAM) |
| MX (1) | MX2014014683A (OSRAM) |
| NZ (1) | NZ702146A (OSRAM) |
| WO (1) | WO2013182661A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2950785A4 (en) * | 2013-02-04 | 2016-09-21 | Univ Notre Dame Du Lac | NANOPARTICLE-drug delivery systems |
| TW201609152A (zh) | 2014-09-03 | 2016-03-16 | 免疫原公司 | 包含細胞結合劑及細胞毒性劑之偶聯物 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| MY189551A (en) * | 2016-06-20 | 2022-02-16 | Isa Pharmaceuticals B V | Formulation of a peptide vaccine |
| MX2019007973A (es) * | 2017-01-03 | 2019-11-18 | Emergex Vaccines Holding Ltd | Composiciones universales de vacuna de la influenza. |
| CN110548136A (zh) * | 2018-05-30 | 2019-12-10 | 王美亮 | 汉坦病毒长肽疫苗 |
| JP7395200B2 (ja) * | 2019-03-25 | 2023-12-11 | イミュンワーク インク． | 金属結合モチーフを有する複合ポリペプチド及びそれを備える分子構築物 |
| KR102393872B1 (ko) * | 2019-08-28 | 2022-05-04 | 엠브릭스 주식회사 | 바이러스 외피를 손상시키는 m2 단백질 유래 항바이러스 펩타이드 및 그의 용도 |
| EP4103587A1 (en) * | 2020-02-14 | 2022-12-21 | Immunor AS | Corona virus vaccine |
| KR102707584B1 (ko) * | 2020-04-02 | 2024-09-19 | 조선대학교산학협력단 | 코로나바이러스 감염증１９의 진단 및 백신을 위한 재조합 뉴클레오캡시드 단백질 및 이의 용도 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4606918A (en) | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| BR9206310A (pt) | 1991-07-25 | 1995-04-25 | Idec Pharma Corp | Indução de respostas citotóxicas de linfócitos T. |
| MA22842A1 (fr) | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
| FI945483A7 (fi) | 1992-05-23 | 1995-01-20 | Smithkline Beecham Biologicals S A | Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| AU685443B2 (en) | 1993-03-23 | 1998-01-22 | Smithkline Beecham Biologicals (Sa) | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| DK0735893T3 (da) | 1993-09-14 | 2009-03-09 | Pharmexa Inc | PAN DR-bindende peptider til styrkelse af immunsvaret |
| EP0979867A3 (en) | 1993-11-04 | 2007-06-13 | Innogenetics N.V. | Immunodominant human T-cell epitopes of hepatitis C virus |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| DE69517521T2 (de) | 1994-04-08 | 2001-03-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville | Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| AU2658897A (en) | 1996-03-21 | 1997-10-10 | Epimmune, Inc. | Hla-a2.1 binding peptides and their uses |
| DK0935662T3 (da) | 1996-05-24 | 2006-03-06 | Chiron Corp | Fusionsprotein med multiple epitoper |
| US6566330B1 (en) | 1996-10-22 | 2003-05-20 | Medical University Of South Carolina Foundation Research Development | Positively charged non-natural amino acids, methods of making and using thereof in peptides |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| DE69918146T2 (de) | 1998-10-05 | 2005-07-07 | Pharmexa A/S | Verfahren zur therapeutischen impfung |
| NO311807B1 (no) * | 1999-03-04 | 2002-01-28 | Bionor Immuno As | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
| EP1200109A4 (en) | 1999-07-19 | 2005-06-15 | Epimmune Inc | USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C |
| US20020076415A1 (en) | 1999-12-14 | 2002-06-20 | Jing-Hsiung Ou | Hepatitis C virus gene products |
| GB0005703D0 (en) | 2000-03-09 | 2000-05-03 | Alpharma As | Compounds |
| JP2004522415A (ja) | 2000-09-01 | 2004-07-29 | エピミューン インコーポレーティッド | Ｈｌａ結合ペプチドおよびその使用方法 |
| NO314588B1 (no) * | 2000-09-04 | 2003-04-14 | Bionor Immuno As | HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV |
| NO314587B1 (no) * | 2000-09-04 | 2003-04-14 | Bionor Immuno As | HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV |
| EP1195381A1 (de) | 2000-09-28 | 2002-04-10 | Immusystems GmbH | CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope |
| GB0026094D0 (en) | 2000-10-25 | 2000-12-13 | Imp College Innovations Ltd | Methods |
| AU2003236728A1 (en) | 2002-06-10 | 2003-12-22 | Algonomics N.V. | Method for predicting the binding affinity of mhc/peptide complexes |
| ES2369664T3 (es) * | 2002-08-12 | 2011-12-02 | The Council Of The Queensland Institute Of Medical Research | Lipopéptidos inmunogénicos novedosos que comprenden epítopos de células t cooperadoras y de células b. |
| JP2006504687A (ja) | 2002-09-13 | 2006-02-09 | インターツェル・アクチェンゲゼルシャフト | Ｃ型肝炎ウイルスペプチドの単離方法 |
| BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
| EP1652858A1 (en) | 2004-10-28 | 2006-05-03 | Innogenetics N.V. | Peptides for inducing a CTL and/or HTL response to hepatitis C virus |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| US8252893B2 (en) | 2005-01-31 | 2012-08-28 | Board Of Trustees Of The University Of Arkansas | CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof |
| WO2008107400A1 (en) * | 2007-03-02 | 2008-09-12 | Genimmune N.V. | Hcv polyepitope construct and uses thereof |
| US9200065B2 (en) * | 2009-07-03 | 2015-12-01 | Bionor Immuno As | Peptide constructs derived from the GP120 C5 domain and GP41 transmembrane domain |
| CN103282375B (zh) | 2010-12-02 | 2017-01-11 | 比奥诺尔免疫有限公司 | 肽支架设计 |
| CN103347892B (zh) | 2011-01-06 | 2016-11-02 | 比奥诺尔免疫有限公司 | 单体和多聚体免疫原性肽 |
| US8618303B2 (en) * | 2011-01-07 | 2013-12-31 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
-
2013
- 2013-06-06 WO PCT/EP2013/061751 patent/WO2013182661A1/en not_active Ceased
- 2013-06-06 EP EP13727202.7A patent/EP2859011B1/en active Active
- 2013-06-06 KR KR20157000273A patent/KR20150018870A/ko not_active Withdrawn
- 2013-06-06 CA CA2874923A patent/CA2874923C/en active Active
- 2013-06-06 IN IN2769KON2014 patent/IN2014KN02769A/en unknown
- 2013-06-06 US US14/406,016 patent/US10501499B2/en active Active
- 2013-06-06 NZ NZ702146A patent/NZ702146A/en not_active IP Right Cessation
- 2013-06-06 EA EA201492262A patent/EA201492262A1/ru unknown
- 2013-06-06 BR BR112014030466A patent/BR112014030466A2/pt not_active IP Right Cessation
- 2013-06-06 AU AU2013273482A patent/AU2013273482A1/en not_active Abandoned
- 2013-06-06 MX MX2014014683A patent/MX2014014683A/es unknown
- 2013-06-06 HK HK15108544.7A patent/HK1207871A1/xx unknown
- 2013-06-06 JP JP2015515530A patent/JP6310909B2/ja not_active Expired - Fee Related
- 2013-06-06 CN CN201380039292.3A patent/CN104619718A/zh active Pending
-
2014
- 2014-11-25 IL IL235891A patent/IL235891A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2874923A1 (en) | 2013-12-12 |
| AU2013273482A1 (en) | 2014-12-11 |
| US20150152140A1 (en) | 2015-06-04 |
| KR20150018870A (ko) | 2015-02-24 |
| BR112014030466A2 (pt) | 2017-09-12 |
| JP6310909B2 (ja) | 2018-04-11 |
| EA201492262A1 (ru) | 2015-08-31 |
| CA2874923C (en) | 2021-08-31 |
| US10501499B2 (en) | 2019-12-10 |
| IL235891A0 (en) | 2015-01-29 |
| JP2015521206A (ja) | 2015-07-27 |
| NZ702146A (en) | 2016-11-25 |
| HK1207871A1 (en) | 2016-02-12 |
| EP2859011B1 (en) | 2019-12-11 |
| CN104619718A (zh) | 2015-05-13 |
| MX2014014683A (es) | 2015-02-24 |
| EP2859011A1 (en) | 2015-04-15 |
| WO2013182661A1 (en) | 2013-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN02769A (OSRAM) | ||
| EA201390806A1 (ru) | Конструкция пептидного каркаса | |
| PH12015501017A1 (en) | Alternative uses for hbv assembly effectors | |
| EA201790630A1 (ru) | Способы получения рибозидов | |
| MX2021001053A (es) | Vacunas contra virus de la influenza y sus usos. | |
| NI201700019A (es) | Anticuerpos anti tigit | |
| PH12016500486A1 (en) | Aza-pyridone compounds and uses thereof | |
| PH12014500557A1 (en) | Methods for treating hcv | |
| PH12013502322A1 (en) | Hendra and nipah virus g glycoprotein immunogenic compositions | |
| MX2013007918A (es) | Peptidos inmunogenicos monomericos y multimericos. | |
| PH12016500492B1 (en) | Pyridazinone compounds and uses thereof | |
| SA515360072B1 (ar) | تحضير بخاري الطور لأكاسيد صلبة فلوريدية | |
| BR112017006680A2 (pt) | variantes de vírus influenza a | |
| EP3939604A3 (en) | Influenza hemagglutinin protein vaccines | |
| UY34420A (es) | ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos" | |
| WO2015058772A3 (en) | Novel hcv culture systems and direct-acting antiviral sensitivity | |
| PH12014502551B1 (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
| PH12014500369A1 (en) | Influenza h5 vaccines | |
| WO2014152946A3 (en) | Polypeptides for treating and/or limiting influenza infection | |
| WO2014065848A3 (en) | Compounds for treating papilloma virus infection | |
| PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
| PH12017500817A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
| PH12015500831A1 (en) | Treatment of viral and infectious diseases using an inhibitor of cbp/catenin | |
| MX360137B (es) | Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento. | |
| MX2016007884A (es) | Biomarcadores para la respuesta al tratamiento del hbv. |